168. Ehlers-Danlos syndrome Clinical trials / Disease details
Clinical trials : 13 / Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05405257 (ClinicalTrials.gov) | May 13, 2022 | 2/6/2022 | Oxytocin for Hypermobile Ehlers-Danlos Syndrome | Oxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos Syndrome | Hypermobile Ehlers-Danlos Syndrome;Pain Assessment | Drug: Oxytocin;Other: Placebo | Baylor College of Medicine | NULL | Enrolling by invitation | 18 Years | 64 Years | Female | 20 | Phase 1/Phase 2 | United States |